Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTX-108
- Development stage
- Phase 2
- Lead developer
- Providence Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PTX-108 is an mRNA-based cancer vaccine developed by Providence Therapeutics for the treatment of pediatric brain cancer. The vaccine utilizes messenger RNA to encode specific pediatric brain tumor antigens, aiming to stimulate the patient's immune system to recognize and mount a targeted response against malignant brain tumor cells. By delivering the genetic instructions for these antigens directly to the patient's cells, PTX-108 facilitates the endogenous production of tumor-specific proteins that are then presented to the immune system. It is currently in Phase 1 clinical development.
Beyond the preview
Go deeper on PTX-108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTX-108.